Milestone Pharmaceuticals is trading 5.98% lower at $0.74 on October 30, 2026, after several consecutive sessions of gains; available price context does not establish a specific catalyst.
- A Nasdaq minimum-bid-price notice may be an overhang; the company has until April 21, 2027, to regain compliance, but its role in the decline is unconfirmed.
- Healthcare was up 2.32%, so sector strength does not explain the stock’s drop.